Crystagen
Also known as: Glu-Asp-Pro · EDP (single-letter amino-acid code) · glutamyl-aspartyl-proline · Crystagenum · Cytogen-class immune peptide
Research focus
Immune tissue — proposed support of splenic lymphocyte (B-cell) function during aging
US regulatory status
Not FDA-approved · Not compoundable
Evidence rating
No Human Data
Origin
Crystagen is a short synthetic peptide attributed to the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology (Russia). It belongs to the "Cytogen" family of rationally designed di-, tri-, and tetra-peptides that the institute has promoted since the 1990s–2000s as putative tissue-specific "peptide bioregulators." Unlike the institute's better-known organ-extract products (the Cytamins) and its flagship synthetic peptides Epitalon and Thymalin/Vilon, Crystagen has only a minimal published footprint. As of 2026 it appears in a single PubMed-indexed study, a 2014 in-vitro report in Advances in Gerontology (Uspekhi Gerontologii). It is most often described as an immune-directed peptide and is commonly listed by secondary and vendor sources as the tripeptide Glu-Asp-Pro (EDP).
Plain-language summary
Crystagen is one of the lesser-known synthetic "peptide bioregulators" from a single Russian research institute, marketed as an immune-support peptide and usually listed as the three-amino-acid chain Glu-Asp-Pro. The short version: there is almost nothing published on it. We could find only one peer-reviewed, PubMed-indexed study, and it was done in a dish on spleen tissue cultures, not in living animals and not in people. In that study Crystagen appeared to "activate" certain immune cells (B-cells) but did not show the tissue-renewing effect seen with some related peptides. There are no human trials, no pharmacokinetic data, and no independent replication. Any claims you see online about Crystagen "boosting immunity" go far beyond what the published evidence can support.
Claimed mechanism (as reported)
The Khavinson group proposes that very short peptides such as Crystagen act as "peptide bioregulators" that penetrate the cell and nucleus and influence gene expression — in this case reportedly modulating immune (lymphocyte) activity. In the one indexed in-vitro study, Crystagen is described as activating B-cells in cultured spleen tissue while, unlike some sibling peptides, not reportedly driving cell renewal in the aging spleen. This proposed DNA/gene-expression-binding mechanism is drawn almost entirely from the group's broader in-silico and in-vitro work on short peptides and has not been demonstrated specifically for Crystagen in humans. The mechanism remains hypothetical and is not independently established.
Evidence summary
The published evidence base for Crystagen is essentially a single in-vitro study. As of 2026, only one PubMed-indexed paper names Crystagen by compound — a 2014 cell/tissue-culture report from the St. Petersburg Institute of Bioregulation and Gerontology examining immune cells in aging spleen tissue (Adv Gerontol / Uspekhi Gerontologii). There are no human studies, no whole-animal efficacy or safety studies indexed under this name, no pharmacokinetic data, and no randomized controlled trials in the peer-reviewed English-language literature. The general "short-peptide regulates gene expression" mechanism is supported only by broader Khavinson-group review and systematic-review articles, which discuss short peptides as a class rather than Crystagen specifically. This profile is therefore graded No Human Data, and the in-vitro finding should be read as a single, unreplicated, single-group result.
What the research reports
[Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process]
Grade DChervyakova NA, Linkova NS, Chalisova NI, Koncevaya EA, Trofimova SV, Khavinson VKh · Advances in Gerontology (Uspekhi Gerontologii) · 2014
Reported finding: Crystagen was reported to activate B-cells in cultured aging spleen tissue but, unlike sibling peptides Vilon and R-1, was reported not to induce cell renewal in the aging spleen. This is the only PubMed-indexed study naming Crystagen and has not been independently replicated.
Sample: Not applicable — in-vitro spleen tissue cultures; no human or animal subjects
Methodology: D — single in-vitro tissue/cell-culture study, single research group, no animal or human data, English abstract of a Russian-language paper
Limitations: In-vitro only; no living-organism data; single group; outcomes are cell-culture markers, not clinical endpoints; sequence not stated in the abstract.
Peptide Regulation of Gene Expression: A Systematic Review
Grade CKhavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR · Molecules · 2021
Reported finding: Proposes the general framework that short (2–7 residue) peptides penetrate the nucleus and interact with DNA and histones to regulate gene expression, offered as the class-level rationale behind Cytogen-type peptides. Does not report Crystagen-specific human or clinical outcomes.
Sample: Review article — no primary subjects
Methodology: C — narrative/systematic review by the originating group; mechanistic hypothesis, not Crystagen-specific efficacy data
Limitations: Authored by the compound's originators; mechanism largely in-silico/in-vitro; provides context, not independent efficacy evidence for Crystagen.
Neuroepigenetic Mechanisms of Action of Ultrashort Peptides (Khavinson-group mechanistic reviews)
Grade CIlina AR, Khavinson VKh, Linkova NS, Petukhov M · International Journal of Molecular Sciences · 2017–2022
Reported finding: Summarize the group's proposed epigenetic/DNA-binding model for ultrashort peptides as a class. Useful for understanding the claimed mechanism but contain no human efficacy or safety data for Crystagen specifically.
Sample: Review articles — no primary subjects
Methodology: C — mechanistic review literature from the originating group; no Crystagen-specific trials
Limitations: Single-group authorship, hypothesis-driven, not independently replicated; do not address Crystagen by name as an efficacy claim.
Administration reported in studies
No human or animal dosing has been published for Crystagen. The single indexed study applied the peptide to spleen tissue and cell cultures in vitro, so there is no established route, dose, frequency, or duration in living organisms. Vendor "research chemical" listings sometimes suggest injectable or sublingual use, but these are not derived from any published clinical protocol. This is a summary of research conditions — not a dosing recommendation and not a protocol endorsed by TPC.
This section reports what published studies describe. It is not a dosing recommendation from TPS.
Safety record
There is no published safety data for Crystagen in humans or animals — no toxicology studies, no adverse-event reporting, and no pharmacokinetic characterization are indexed for this compound. The originating group describes its short peptides broadly as well tolerated, but that general assertion has not been tested for Crystagen in any controlled human or animal study, and absence of reported harm is not evidence of safety. Material sold online is unregulated, of unverified identity and purity, and has not been tested by TPC. Anyone considering it should recognize that its safety profile is effectively unknown.
US legal status
Not FDA-approved. Not on the FDA 503A compoundable bulk drug substances list. Not legally compoundable for human clinical use in the United States. Sold online only as a "research chemical" — vendors in that channel are unregulated and not verified by TPC.
Open research questions
- ? Does the single in-vitro B-cell 'activation' finding translate to any measurable effect in a living organism, and can it be replicated by a group independent of the St. Petersburg institute?
- ? What is Crystagen's actual amino-acid sequence and purity? Secondary sources list Glu-Asp-Pro (EDP), but the one indexed study does not print the sequence, leaving identity uncertain.
- ? Are there any pharmacokinetic data — is an orally or sublingually administered tripeptide even absorbed intact, or is it simply digested into its constituent amino acids?
- ? What is the human safety and toxicology profile across any meaningful dose range and duration, given that none has ever been published?
Get new bioregulator research as it publishes
Summaries of the Russian and English-language literature, bias-checked and plainly framed.
Subscribe Free →